×

Biomarkers

SCLC has metabolically different, targetable subtypes

SCLC has metabolically different, targetable subtypes

A diagnosis of small-cell lung cancer (SCLC) carries with it a grim prognosis. Standard therapy for extensive-stage disease, which consists of combination chemotherapy and radiation, is associated with 5-year overall survival rates of just 5%-10%.

read more
B7-H3 stands out as future SCLC target

B7-H3 stands out as future SCLC target

B7-H3 stands out as future SCLC targetBY CHRISTINE KILGORE MDedge News FROM THE JOURNAL FOR IMMUNOTHERAPY OF CANCER About two out of three patients with small cell lung cancer (SCLC) express B7-H3, a B7 family ligand that may one day serve as a therapeutic target,...

read more

Continue Reading


Biomarkers


+

Prevention


+

Cost And Coping


+

Diagnosis and Therapy


+

Patient Journey


+